# A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies

> **NCT07477548** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Yonsei University** · enrollment: 67 (estimated)

## Conditions studied

- Vascular Malformations
- Arteriovenous Malformations
- Venous Malformation
- Lymphangioma
- Nevus, Port-Wine
- Hemangioendothelioma
- Hemangioma

## Interventions

- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT07477548
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2030-10-31
- **Final completion:** 2030-11-30
- **Target enrollment:** 67 (ESTIMATED)
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07477548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07477548, "A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07477548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*